With Benefits Upgrades, Walmart Ups the Ante in War for Retail Talent

Retail giant Walmart recently announced a significant overhaul and enhancement to its employee healthcare benefits package, beginning in 2027. Moving aggressively to counter some competitors that have scaled back healthcare offerings amid rising macroeconomic pressures, the nation’s largest private employer (around 1.6 million employees) introduced:

A comprehensive “$0 prescription tier”;
Full coverage of glucagon-like peptide-1 (GLP-1) medications for diabetes management;
Enhanced specialist networks for rare diseases; and,
A dedicated, paid neonatal intensive care leave program.

The changes, captured within Walmart’s open enrollment offering for the 2027 plan year (signup closed Friday, Nov. 6), are bold yet transparent. By taking on the added benefit costs, the company is seeking to minimize employee turnover, which is a challenge for many employers, but particularly those in the retail sector. Retention improvement by even a few percentage points has the potential to generate immense bottom-line savings, with the biggest cost returns coming from reduced expenditures tied to recruiting and onboarding. Walmart extends healthcare coverage to its full-time staff and part-time workers averaging at least 30 hours per week.

Central to the 2027 plan restructure is a new zero-cost prescription tier encompassing more than 250 generic, brand-name and specialty medications. According to a corporate memo issued by Walmart chief people officer Donna Morris, this list is constructed around essential maintenance therapies, including various inhalers and insulin products. However, the package also incorporates coverage for specific GLP-1 receptor agonists used in treating Type 2 diabetes. The medications (namely, Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro) will be subject to clinical prior authorization. The company purposely excluded coverage for GLP-1s prescribed solely for weight loss or obesity. That stance mirrors recent benefit adjustments by major employers that are trying to protect themselves from escalating pharmaceutical liabilities.

Walmart also broadened its “Centers of Excellence” (COE) program (which connects employees with premier healthcare institutions for complex treatments such as cancer) to include a dedicated Rare Conditions COE. With the expansion, employees and dependents facing serious diagnoses (e.g., multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis) receive zero-cost, in-person access to specialists at the Mayo Clinic and Cleveland Clinic, complete with fully funded travel and lodging for the patient and a caregiver.

In addition, the retailer introduced up to 12 weeks of fully paid neonatal intensive care unit (NICU) leave for employees whose newborns require inpatient admission during their first 28 days of life. Because this policy is stackable with existing parental leave under the federal Family and Medical Leave Act, frontline workers can receive up to 28 weeks of total paid time off for complex birth cases.

Editor’s Note: Additional Content

For more information and resources related to this article, see the pages below, which offer quick access to all WorldatWork content on these topics: